Latest News for: tki

Edit

123Invent Inventor Develops the Saving Lives Shield (TKI-1259)

PR Newswire 13 Jan 2026
PITTSBURGH, Jan. 13, 2026 /PRNewswire/ -- "I was moved to invent the Saving Lives Shield after watching daily world news reports of mass shootings in schools, churches, hospitals, military bases, malls, and more ... SOURCE InventHelp. 21% ... .
Edit

123Invent Inventor Develops Specially Designed Hunting Shack (TKI-1262)

PR Newswire 13 Jan 2026
PITTSBURGH, Jan ... My design would also help you keep warm and comfortable when hunting in cold conditions.". The patent-pending invention provides an improved shack for hunters ... SOURCE InventHelp. 21% ... .
Edit

HANSOH PHARMA | AMEILE’S FIFTH INDICATION FOR “TARGETED THERAPY PLUS CHEMOTHERAPY” APPROVED, MARKING FULL-COURSE COVERAGE OF CHINA’S ORIGINAL THIRD-GENERATION EGFR-TKI (Hansoh Pharmaceutical Group Co Ltd)

Public Technologies 12 Jan 2026
AMEILE'S FIFTH INDICATION FOR "TARGETED THERAPY PLUS CHEMOTHERAPY" APPROVED, MARKING FULL-COURSE COVERAGE OF CHINA'S ORIGINAL THIRD-GENERATION EGFR-TKI ... Ameile is the first original third-generation EGFR-TKI innovative drug in China.
Edit

Początki nowego - Astrorado 30/12/2025 start 18.00

Rumble 30 Dec 2025
Click the Rumble article link to see the video ....
Edit

123Invent Inventor Develops Improved Hardware Item (TKI-1270)

PR Newswire 22 Dec 2025
PITTSBURGH , Dec ... My design would offer a more effective and affordable option than traditional mounts and hardware items.". The invention provides an improved hardware item for mounting or attaching items to a wall ... SOURCE InventHelp. 21% ... .
Edit

Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma (Glenmark Pharmaceuticals Limited)

Public Technologies 16 Dec 2025
) Glenmark Secures Exclusive Multi-Regional Rights to Aumolertinib, an MHRA and NMPA approved Third-Generation EGFR-TKI, from Hansoh Pharma ... China-developed EGFR-TKI to be launched internationally.
Edit

123Invent Inventor Develops New Accessory for Sports Fans (TKI-1261)

PR Newswire 02 Dec 2025
PITTSBURGH, Dec ... My design can be easily applied onto the nose to show that a call, play, or team stinks.". The invention provides a new accessory for sports enthusiasts ... SOURCE InventHelp. 21%. more press release views with. Request a Demo. .
Edit

DeltaV’den Yerli Ramjet İtki Sistemi Test Başarısı

Istiklal 23 Nov 2025
Tarafsız ve güvenilir habercilik için tıklayın ....
Edit

Final Overall Survival Analysis : HARMONi-A Study Ivonescimab + chemotherapy versus Chemotherapy In patients with EGFR-mutant NSCLC progressed on EGFR TKI (Summit Therapeutics Inc)

Public Technologies 21 Nov 2025
EGFR-mutant NSCLC progressed on EGFR TKI ... EGFR, epidernal growth factor receptor; TKI, tyrosine-kinase inhibitor; ICI, innune checkpoint inhibitor; PD-1, progranned death-1; PD-L1, progranned death ligand 1; PFS, progression-free survival.
Edit

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI ...

Citizen Tribune 19 Nov 2025
NDA based on data from global ARROS-1 Phase 1/2 clinical trial ....
Edit

Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC

PR Newswire 19 Nov 2025
... kinase inhibitor (TKI) ... The ongoing global, single arm, open label Phase 2 portion is designed with registrational intent for TKI-naïve and TKI pre-treated patients with advanced ROS1-positive NSCLC.
Edit

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated ...

Citizen Tribune 17 Nov 2025
In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI. 26, 37), with initial estimated durability of response of 64% and 53% at the 12-month and 18-month landmarks, respectivelyIn the subset of 63 TKI pre-treated patients who ....
Edit

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC

PR Newswire 17 Nov 2025
In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI ... Efficacy Analysis in TKI Pre-treated Advanced ALK-positive NSCLC ... Of the overall TKI pre-treated population, 25% (63/253) of patients were lorlatinib-naïve ... TKI Pre-treated,.
Edit

Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC (Nuvalent Inc)

Public Technologies 17 Nov 2025
Nuvalent Announces Positive Topline Pivotal Data from ALKOVE-1 Clinical Trial of Neladalkib for TKI Pre-treated Patients with Advanced ALK-positive NSCLC In 253 ALK TKI pre-treated patients, ORR by BICR was 31% (95% CI ... Any prior ALK TKI.
Edit

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC ...

The Galveston Daily News 14 Nov 2025
Company to host webcast and conference call on November 17, 2025 at 8.00am ET ....

Article Search

tools
×
×
×
×